查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1428596

皮膚科藥物市場：2024-2034

Dermatological Drugs Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2034 年，全球皮膚科藥物市場規模將以 10.5% 的複合年增長率成長。

隨著世界人口以前所未有的速度老化，皮膚科藥品市場預計將大幅擴張。根據世界衛生組織（WHO）預測，到2050年，80%的老年人將居住在低收入和中等收入國家。人口老化的迅速加速超過了過去的趨勢，預計將成為關鍵驅動因素。據世界衛生組織稱，到 2030 年，六分之一的人將超過 60 歲。此外，2021年至2050年，亞洲65歲及以上人口將增加5億以上，皮膚科用藥市場預計將快速擴大。這種人口結構的變化意味著對解決與年齡相關的皮膚病問題（例如皺紋、老年斑和老年人常見的皮膚狀況）的皮膚護理解決方案的需求增加。因此，在不斷增長的老年人口需求的推動下，未來幾年皮膚科製藥業預計將利潤豐厚。

在不斷變化的皮膚病學領域，尖端技術在藥物傳輸中的整合有望將市場推向前所未有的高度。奈米技術的出現可以精確地靶向皮膚細胞，提高皮膚科藥物的功效，同時最大限度地減少副作用。這種創新方法可確保更量身定制和高效的治療，從而改善患者的治療效果和滿意度。微針技術正在重塑皮膚科藥物的傳遞方式。這些微創裝置可無痛地穿透皮膚並促進治療劑的受控和持續釋放。這不僅提高了患者的依從性，也優化了藥物吸收，從而獲得更快、更有效的結果。

本報告調查了全球皮膚科藥物市場，並提供了市場概況、影響市場成長和市場機會的因素分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭狀況和主要市場機會。簡介等

目錄

第 1 章報告概述

第 2 章執行摘要

第 3 章市場概況

  • 主要發現
  • 市場動態
    • 市場驅動力
    • 市場制約因素
    • 市場機會
  • COVID-19 影響分析
  • 波特五力分析
  • PEST分析

第四章皮膚科藥物市場分析：依給藥途徑

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 當地的
  • 口服
  • 腸外
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第五章皮膚科藥物市場分析：依疾病分類

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 銀屑病
  • 皮膚炎
  • 粉刺
  • 皮膚感染
  • 其他
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第六章皮膚科藥物市場分析：依處方模式

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 處方藥
  • 非處方藥 (OTC)
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第七章皮膚科藥品市場分析：依通路

  • 主要發現
  • 市場吸引力指數
  • 市場規模趨勢和預測
  • 零售藥店
  • 醫院藥房
  • 網上藥店
  • 其他
    • 市場規模趨勢與預測：按地區
    • 市佔率：按地區

第八章皮膚科藥物市場分析：按地區

  • 主要發現
  • 市場規模趨勢和預測

第九章北美皮膚科藥品市場分析

第十章歐洲皮膚科藥品市場分析

第十一章亞太皮膚科藥品市場分析

第十二章拉丁美洲皮膚科藥品市場分析

第十三章中東及非洲皮膚科藥品市場分析

第十四章公司簡介

  • 競爭格局
  • 戰略視角
  • Novartis AG
  • Bayer AG
  • LEO Pharma A/S
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Regeneron Pharmaceuticals Inc.
  • AbbVie Inc.
  • Verrica Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Roivant Sciences Ltd.
  • DermBiont, Inc.
  • AstraZeneca
  • Merck & Co., Inc.
  • GSK plc
  • F. Hoffmann-La Roche Ltd
  • Mayne Pharma Group Limited

第十五章 一般性意見/建議

  • Visiongain 的一般討論
  • 對參賽者的建議
Product Code: PHA1306

The global Dermatological Drugs Market is projected to grow at a CAGR 10.5% by 2034

The Dermatological Drugs Market Report 2024-2034: This report is essential for prominent enterprises seeking fresh revenue opportunities, aiming to enhance their comprehension of the industry and its inherent dynamics. It provides valuable insights for firms interested in diversifying across various sectors or expanding their current activities into new geographical areas.

Geriatric Population Driving Demand for Dermatological Drugs

As the global population ages at an unprecedented pace, the dermatological drugs market is poised for a significant upswing. According to the World Health Organization (WHO), by 2050, 80% of older individuals will reside in low- and middle-income countries. The rapid acceleration in population aging, outpacing historical trends, is a key catalyst. As per WHO, by 2030, one in every 6 person will be aged 60 or over. Also, from 2021 to 2050, population aged over 65 in Asia will grow by more than half-a-billion, creating a burgeoning market for dermatological drugs. This demographic shift signifies an increased demand for skincare solutions tailored to age-related dermatological concerns, such as wrinkles, age spots, and skin conditions prevalent in the elderly. Thus, the coming years will mark a lucrative era for the dermatological drugs industry, driven by the unique needs of the expanding geriatric population.

Nanotechnology in Drug Delivery Could Revolutionize the Dermatological Drugs Market

In the dynamic landscape of dermatology, the integration of cutting-edge technological advancements in drug delivery is poised to propel the market to unprecedented heights. The advent of nanotechnology enables precise targeting of skin cells, enhancing the efficacy of dermatological drugs while minimizing side effects. This revolutionary approach ensures a more tailored and efficient treatment, boosting patient outcomes and satisfaction. Micro-needle technology is reshaping the administration of dermatological drugs. These minimally invasive devices painlessly penetrate the skin, facilitating controlled and sustained release of therapeutic agents. This not only improves patient compliance but also optimizes drug absorption, leading to quicker and more effective results. Several companies are actively researching and developing nanocarriers and smart delivery systems for skincare applications such as NanoVibronix (US) and Nanologica (Sweden).

Furthermore, the incorporation of smart polymers in drug formulations represents a paradigm shift in dermatological treatments. These polymers respond to specific physiological cues, releasing drugs at the right time and in the right amounts. This precision enhances therapeutic outcomes, reduces the frequency of application, and minimizes adverse reactions.

What Questions Should You Ask before Buying a Market Research Report?

How is the Dermatological Drugs market evolving?

What is driving and restraining the Dermatological Drugs market?

How will each Dermatological Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Dermatological Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Dermatological Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Dermatological Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Dermatological

Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Dermatological Drugs market?

Where is the Dermatological Drugs market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Dermatological Drugs market today, and over the next 10 years:

Our 280-page report provides 113 tables and 160 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Dermatological Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Dermatological Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Route of Administration

Topical

Oral

Parenteral Administration

Disease

Psoriasis

Dermatitis

Acne

Skin Infections

Others

Prescription Mode

Prescription Drugs

Over-the-Counter (OTC) Drugs

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Dermatological Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

AstraZeneca

Bayer AG

DermBiont, Inc.

F. Hoffmann-La Roche Ltd

GSK plc

Johnson & Johnson Services, Inc.

LEO Pharma A/S

Mayne Pharma Group Limited

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Regeneron Pharmaceuticals Inc.

Roivant Sciences Ltd.

Teva Pharmaceutical Industries Ltd.

Verrica Pharmaceuticals

Overall world revenue for Dermatological Drugs Market, 2024 to 2034 in terms of value the market will surpass US$30.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Dermatological Drugs Market, 2024 to 2034 report help you?

In summary, our 280-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Dermatological Drugs Market 2024 to 2034, with forecasts for route of administration, disease, prescription mode, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 21 key national markets - See forecasts for the Dermatological Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Dermatological Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Dermatological Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Dermatological Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of Skin Disorders
      • 3.2.1.2 Growing Awareness and Patient Education
      • 3.2.1.3 Globalization and Urbanization
      • 3.2.1.4 Revolutionizing Dermatology: Unleashing Market Growth Through Advanced Drug Delivery Technologies
      • 3.2.1.5 Innovative Breakthroughs: Propelling Dermatological Drugs Market Through Surging R&D Investments
      • 3.2.1.6 Geriatric Population Driving Dermatological Drugs Market
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Generic Competition
      • 3.2.2.2 Adverse Effects and Safety Concerns
      • 3.2.2.3 Drug Resistance
      • 3.2.2.4 Non-Pharmacological Options: A Hindrance to Dermatological Drugs Market Growth
      • 3.2.2.5 Limited Reimbursement and Coverage Challenges in Dermatological Drugs Sector
      • 3.2.2.6 Regulatory Approval Process Poses Barriers to Dermatological Drugs Market Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Approval of Novel Dermatological Drugs
      • 3.2.3.2 Advancements in Dermatology Research and Technology
      • 3.2.3.3 Telemedicine and E-Health
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political
    • 3.5.2 Economical
    • 3.5.3 Social
    • 3.5.4 Technological

4 Dermatological Drugs Market Analysis by Route of Administration

  • 4.1 Key Findings
  • 4.2 Route of Administration Segment: Market Attractiveness Index
  • 4.3 Dermatological Drugs Market Size Estimation and Forecast by Route of Administration
  • 4.4 Topical
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Oral
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Parenteral
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Dermatological Drugs Market Analysis by Disease

  • 5.1 Key Findings
  • 5.2 Disease Segment: Market Attractiveness Index
  • 5.3 Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 5.4 Psoriasis
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Dermatitis
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Acne
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Skin Infections
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Others
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Dermatological Drugs Market Analysis by Prescription Mode

  • 6.1 Key Findings
  • 6.2 Prescription Mode Segment: Market Attractiveness Index
  • 6.3 Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 6.4 Prescription Drugs
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Over-the-Counter (OTC) Drugs
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Dermatological Drugs market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Dermatological Drugs market Size Estimation and Forecast by Distribution Channel
  • 7.4 Retail Pharmacies
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Hospital Pharmacies
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Online Pharmacies
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Others
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Dermatological Drugs Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Dermatological Drugs Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Dermatological Drugs Market Attractiveness Index
  • 9.3 North America Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 North America Dermatological Drugs Market Size Estimation and Forecast by Country
  • 9.5 North America Dermatological Drugs Market Size Estimation and Forecast by Component
  • 9.6 North America Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 9.7 North America Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 9.8 North America Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.9 U.S. Dermatological Drugs Market Analysis
  • 9.10 Canada Dermatological Drugs Market Analysis

10 Europe Dermatological Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Dermatological Drugs Market Attractiveness Index
  • 10.3 Europe Dermatological Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Europe Dermatological Drugs market Size Estimation and Forecast by Country
  • 10.5 Europe Dermatological Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.6 Europe Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 10.7 Europe Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 10.8 Europe Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.9 Germany Dermatological Drugs Market Analysis
  • 10.10 France Dermatological Drugs market Analysis
  • 10.11 U.K. Dermatological Drugs market Analysis
  • 10.12 Italy Dermatological Drugs market Analysis
  • 10.13 Spain Dermatological Drugs Market Analysis
  • 10.14 Rest of Europe Dermatological Drugs market Analysis

11 Asia Pacific Dermatological Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Dermatological Drugs Market Attractiveness Index
  • 11.3 Asia Pacific Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Component
  • 11.6 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 11.7 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 11.8 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.9 China Dermatological Drugs Market Analysis
  • 11.10 India Dermatological Drugs Market Analysis
  • 11.11 Japan Dermatological Drugs Market Analysis
  • 11.12 Australia Dermatological Drugs Market Analysis
  • 11.13 South Korea Dermatological Drugs Market Analysis
  • 11.14 Rest of Asia Pacific Dermatological Drugs market Analysis

12 Latin America Dermatological Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Dermatological Drugs Market Attractiveness Index
  • 12.3 Latin America Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Latin America Dermatological Drugs Market Size Estimation and Forecast by Country
  • 12.5 Latin America Dermatological Drugs Market Size Estimation and Forecast by Component
  • 12.6 Latin America Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 12.7 Latin America Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 12.8 Latin America Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Brazil Dermatological Drugs Market Analysis
  • 12.10 Mexico Dermatological Drugs market Analysis
  • 12.11 Rest of Latin America Dermatological Drugs Market Analysis

13 MEA Dermatological Drugs market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Dermatological Drugs Market Attractiveness Index
  • 13.3 MEA Dermatological Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 MEA Dermatological Drugs Market Size Estimation and Forecast by Country
  • 13.5 MEA Dermatological Drugs Market Size Estimation and Forecast by Component
  • 13.6 MEA Dermatological Drugs Market Size Estimation and Forecast by Disease
  • 13.7 MEA Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
  • 13.8 MEA Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.9 GCC Dermatological Drugs market Analysis
  • 13.10 South Africa Dermatological Drugs market Analysis
  • 13.11 Rest of MEA Dermatological Drugs market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2023
  • 14.2 Strategic Outlook
  • 14.3 Novartis AG
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2018-2022
      • 14.3.3.2 Regional Market Shares, 2022
      • 14.3.3.3 R&D Expense, 2018-2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2018-2022
      • 14.4.3.2 Regional Market Shares, 2022
      • 14.4.3.3 R&D Expense, 2018-2022
    • 14.4.4 Product Benchmarking
  • 14.5 LEO Pharma A/S
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Product Benchmarking
    • 14.5.4 Strategic Outlook
  • 14.6 Pfizer Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Revenue, 2018-2022
      • 14.6.3.2 Regional Market Shares, 2022
      • 14.6.3.3 R&D Expense, 2018-2022
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Johnson & Johnson Services, Inc.
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Revenue, 2018-2022
      • 14.7.3.2 Regional Market Shares, 2022
      • 14.7.3.3 R&D Expense, 2018-2022
    • 14.7.4 Product Benchmarking
  • 14.8 Regeneron Pharmaceuticals Inc.
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Revenue, 2018-2022
      • 14.8.3.2 R&D Expense, 2018-2022
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 AbbVie Inc.
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Revenue, 2018-2022
      • 14.9.3.2 Regional Market Shares, 2022
      • 14.9.3.3 R&D Expense, 2018-2022
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Verrica Pharmaceuticals
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Product Benchmarking
  • 14.11 Teva Pharmaceutical Industries Ltd.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Revenue, 2018-2022
      • 14.11.3.2 Regional Market Shares, 2022
      • 14.11.3.3 R&D Expense, 2018-2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 Roivant Sciences Ltd.
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Product Benchmarking
    • 14.12.4 Strategic Outlook
  • 14.13 DermBiont, Inc.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Product Benchmarking
    • 14.13.4 Strategic Outlook
  • 14.14 AstraZeneca
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2017-2022
      • 14.14.3.2 Regional Market Shares, 2022
      • 14.14.3.3 R&D Expense, 2018-2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Merck & Co., Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2022
      • 14.15.3.2 Regional Market Shares, 2022
      • 14.15.3.3 R&D Expense, 2017-2022
    • 14.15.4 Product Benchmarking
  • 14.16 GSK plc
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
      • 14.16.3.2 Regional Market Shares, 2022
      • 14.16.3.3 R&D Expense, 2017-2022
    • 14.16.4 Product Benchmarking
  • 14.17 F. Hoffmann-La Roche Ltd
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2018-2022
      • 14.17.3.2 R&D Expense, 2018-2022
    • 14.17.4 Product Benchmarking
  • 14.18 Mayne Pharma Group Limited
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2020-2023
      • 14.18.3.2 R&D Expense, 2020-2023
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Dermatological Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
  • Table 2 Dermatological Drugs Market Forecast by Region 2024-2034 (US$ Bn, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Dermatological Drugs Market Forecast by Region 2024-2034 (US$ Bn, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Dermatological Drugs Market Forecast by Region 2024-2034 (US$ Bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Dermatological Drugs Market Forecast by Region 2024-2034 (US$ Bn, AGR%, CAGR%): "W" Shaped Recovery
  • Table 6 Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 7 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 8 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 9 Hardware Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 10 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 11 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 12 Dermatitis Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 13 Acne Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 14 Skin Infections Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 15 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 16 Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 17 Prescription Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 18 Over-the-Counter (OTC) Drugs Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 19 Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 20 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 21 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 22 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 23 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 24 Dermatological Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 25 North America Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 26 North America Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 27 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 28 North America Dermatological Drugs Market Forecast by Prescription Mode 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 29 North America Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 30 U.S. Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 31 Canada Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 32 Europe Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 33 Europe Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 34 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 35 Europe Dermatological Drugs Market Forecast by Prescription Mode 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 36 Europe Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 37 Germany Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 38 France Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 39 U.K. Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 40 Italy Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 41 Spain Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 42 Rest of Europe Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 43 Asia Pacific Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 44 Asia Pacific Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 45 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 46 Asia Pacific Dermatological Drugs Market Forecast by Prescription Mode 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 47 Asia Pacific Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 48 China Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 49 India Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 50 Japan Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 51 Australia Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 52 South Korea Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 53 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 54 Latin America Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 55 Latin America Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 56 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 57 Latin America Dermatological Drugs Market Forecast by Prescription Mode 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 58 Latin America Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 59 Brazil Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 60 Mexico Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 61 Rest of Latin America Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 62 MEA Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 63 MEA Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 64 Dermatological Drugs Market Forecast by Disease 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 65 MEA Dermatological Drugs Market Forecast by Prescription Mode 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 66 MEA Dermatological Drugs Market Forecast by Distribution Channel 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 67 GCC Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 68 South Africa Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 69 Rest of MEA Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
  • Table 70 Strategic Outlook
  • Table 71 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 72 Novartis AG: Product Benchmarking
  • Table 73 Novartis AG: Strategic Outlook
  • Table 74 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 75 Bayer AG: Product Benchmarking
  • Table 76 LEO Pharma A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 LEO Pharma A/S: Product Benchmarking
  • Table 78 LEO Pharma A/S: Strategic Outlook
  • Table 79 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 Pfizer Inc.: Product Benchmarking
  • Table 81 Pfizer Inc.: Strategic Outlook
  • Table 82 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 84 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 Regeneron Pharmaceuticals Inc.: Product Benchmarking
  • Table 86 Regeneron Pharmaceuticals Inc.: Strategic Outlook
  • Table 87 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 AbbVie Inc.: Product Benchmarking
  • Table 89 AbbVie Inc.: Strategic Outlook
  • Table 90 Verrica Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Verrica Pharmaceuticals: Product Benchmarking
  • Table 92 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
  • Table 94 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
  • Table 95 Roivant Sciences Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 Roivant Sciences Ltd.: Product Benchmarking
  • Table 97 Roivant Sciences Ltd.: Strategic Outlook
  • Table 98 DermBiont, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 DermBiont, Inc.: Product Benchmarking
  • Table 100 DermBiont, Inc.: Strategic Outlook
  • Table 101 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 AstraZeneca: Product Benchmarking
  • Table 103 AstraZeneca: Strategic Outlook
  • Table 104 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Merck & Co., Inc.: Product Benchmarking
  • Table 106 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 GSK plc: Product Benchmarking
  • Table 108 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 110 Mayne Pharma Group Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Mayne Pharma Group Limited: Product Benchmarking
  • Table 112 Mayne Pharma Group Limited: Strategic Outlook
  •  

List of Figures

  • Figure 1 Dermatological Drugs Market Segmentation
  • Figure 2 Dermatological Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 3 Dermatological Drugs Market Forecast by Disease: Market Attractiveness Index
  • Figure 4 Dermatological Drugs Market Forecast by Prescription Mode: Market Attractiveness Index
  • Figure 5 Dermatological Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 6 Dermatological Drugs Market Attractiveness Index by Region
  • Figure 7 Dermatological Drugs Market: Market Dynamics
  • Figure 8 Dermatological Drugs Market by region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "V" Shaped Recovery
  • Figure 9 Dermatological Drugs market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "U" Shaped Recovery
  • Figure 10 Dermatological Drugs market by region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "W" Shaped Recovery
  • Figure 11 Dermatological Drugs market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): "L" Shaped Recovery
  • Figure 12 Dermatological Drugs Market: Porter's Five Forces Analysis
  • Figure 13 Dermatological Drugs: PEST Analysis
  • Figure 14 Dermatological Drugs Market Forecast by Route of Administration: Market Attractiveness Index
  • Figure 15 Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 16 Dermatological Drugs market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
  • Figure 17 Topical Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 18 Topical Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 19 Oral Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 20 Oral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 22 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 23 Dermatological Drugs Market Forecast by Disease: Market Attractiveness Index
  • Figure 24 Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 25 Dermatological Drugs market Share Forecast by Therapeutic Application, 2024, 2029, 2034 (%)
  • Figure 26 Psoriasis Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 27 Oncology Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 28 Dermatitis Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 29 Dermatitis Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 30 Acne Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 31 Acne Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 32 Skin Infections Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 33 Respiratory Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 34 Others Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 35 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 36 Dermatological Drugs Market Forecast by Prescription Mode: Market Attractiveness Index
  • Figure 37 Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 38 Dermatological Drugs Market Share Forecast by Prescription Mode, 2024, 2029, 2034 (%)
  • Figure 39 Prescription Drugs Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 40 Prescription Drugs Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Over-the-Counter (OTC) Drugs Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 42 Over-the-Counter (OTC) Drugs Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 43 Dermatological Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
  • Figure 44 Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 45 Dermatological Drugs market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 46 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 47 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 49 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 51 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 52 Others Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 53 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 54 Dermatological Drugs Market Forecast by Region 2024 & 2034 (Revenue, CAGR%)
  • Figure 55 Dermatological Drugs market Share Forecast by Region 2024, 2029, 2034(%)
  • Figure 56 Dermatological Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
  • Figure 57 North America Dermatological Drugs Market Attractiveness Index
  • Figure 58 North America Dermatological Drugs Market by region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 59 North America Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ billion)
  • Figure 60 North America Dermatological Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 61 North America Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 62 North America Dermatological Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 63 North America Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 64 North America Dermatological Drugs Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 65 North America Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 66 North America Dermatological Drugs Market Share Forecast by Prescription Mode, 2024 & 2034 (%)
  • Figure 67 North America Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 68 North America Dermatological Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 69 U.S. Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 70 Canada Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 71 Europe Dermatological Drugs Market Attractiveness Index
  • Figure 72 Europe Dermatological Drugs market by region, 2024, 2029 & 2034 (US$ billion)
  • Figure 73 Europe Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 74 Europe Dermatological Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 75 Europe Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 76 Europe Dermatological Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 77 Europe Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 78 Europe Dermatological Drugs Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 79 Europe Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 80 Europe Dermatological Drugs Market Share Forecast by Prescription Mode, 2024 & 2034 (%)
  • Figure 81 Europe Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 82 Europe Dermatological Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 83 Germany Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 France Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 85 U.K. Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 Italy Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 87 Spain Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 88 Rest of Europe Dermatological Drugs Market Forecast, 2024-2034 (US$ billion, AGR %)
  • Figure 89 Asia Pacific Dermatological Drugs Market Attractiveness Index
  • Figure 90 Asia Pacific Dermatological Drugs market by Region, 2024, 2029 & 2034 (US$ billion)
  • Figure 91 Asia Pacific Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ billion)
  • Figure 92 Asia Pacific Dermatological Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 93 Asia Pacific Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 94 Asia Pacific Dermatological Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 95 Asia Pacific Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 96 Asia Pacific Dermatological Drugs Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 97 Asia Pacific Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 98 Asia Pacific Dermatological Drugs Market Share Forecast by Prescription Mode, 2024 & 2034 (%)
  • Figure 99 Asia Pacific Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 100 Asia Pacific Dermatological Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 101 China Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 India Dermatological Drugs Market Forecast, 2024-2034 (US$ billion, AGR %)
  • Figure 103 Japan Dermatological Drugs Market Forecast, 2024-2034 (US$ billion, AGR %)
  • Figure 104 Australia Dermatological Drugs Market Forecast, 2024-2034 (US$ billion, AGR %)
  • Figure 105 South Korea Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Rest of Asia Pacific Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 107 Latin America Dermatological Drugs Market Attractiveness Index
  • Figure 108 Latin America Dermatological Drugs market by Region, 2024, 2029 & 2034 (US$ billion)
  • Figure 109 Latin America Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 110 Latin America Dermatological Drugs Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 111 Latin America Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 112 Latin America Dermatological Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 113 Latin America Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 114 Latin America Dermatological Drugs Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 115 Latin America Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 116 Latin America Dermatological Drugs Market Share Forecast by Prescription Mode, 2024 & 2034 (%)
  • Figure 117 Latin America Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 118 Latin America Dermatological Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 119 Brazil Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 120 Mexico Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 121 Rest Of Latin America Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 122 MEA Dermatological Drugs Market Attractiveness Index
  • Figure 123 MEA Dermatological Drugs Market by region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 124 MEA Dermatological Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 125 MEA Dermatological Drugs market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 126 MEA Dermatological Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
  • Figure 127 MEA Dermatological Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
  • Figure 128 MEA Dermatological Drugs Market Forecast by Disease, 2024-2034 (US$ Billion)
  • Figure 129 MEA Dermatological Drugs Market Share Forecast by Disease, 2024 & 2034 (%)
  • Figure 130 MEA Dermatological Drugs Market Forecast by Prescription Mode, 2024-2034 (US$ Billion)
  • Figure 131 MEA Dermatological Drugs Market Share Forecast by Prescription Mode, 2024 & 2034 (%)
  • Figure 132 MEA Dermatological Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion)
  • Figure 133 MEA Dermatological Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
  • Figure 134 GCC Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 135 South Africa Dermatological Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 136 Rest of MEA Dermatological Drugs market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 137 Dermatological Drugs Market: Company Share Analysis, 2023
  • Figure 138 Novartis AG: Net Revenue, 2018-2022 (US$ Billion, AGR%)
  • Figure 139 Novartis AG: Regional Market Shares, 2022
  • Figure 140 Novartis AG: R&D Expense, 2018-2022 (US$ Billion, AGR%)
  • Figure 141 Bayer AG: Net Revenue, 2018-2022 (US$ Billion, AGR%)
  • Figure 142 Bayer AG: Regional Market Shares, 2022
  • Figure 143 Bayer AG: R&D Expense, 2018-2022 (US$ Billion, AGR%)
  • Figure 144 Pfizer Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 145 Pfizer Inc.: Regional Market Shares, 2022
  • Figure 146 Pfizer Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 147 Johnson & Johnson Services, Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 148 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
  • Figure 149 Johnson & Johnson Services, Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 150 Regeneron Pharmaceuticals Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 151 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 152 AbbVie Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 153 AbbVie Inc.: Regional Market Shares, 2022
  • Figure 154 AbbVie Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 155 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 156 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
  • Figure 157 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
  • Figure 158 AstraZeneca: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 159 AstraZeneca: Regional Market Shares, 2022
  • Figure 160 AstraZeneca: R&D Expense, 2017-2022 (US$ Billion, AGR%)
  • Figure 161 Merck & Co., Inc.: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 162 Merck & Co., Inc.: Regional Market Shares, 2022
  • Figure 163 Merck & Co., Inc.: R&D Expense, 2017-2022 (US$ Billion, AGR%)
  • Figure 164 GSK plc: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 165 GSK plc: Regional Market Shares, 2022
  • Figure 166 GSK plc: R&D Expense, 2017-2022 (US$ Billion, AGR%)
  • Figure 167 F. Hoffmann-La Roche Ltd: Net Revenue, 2018-2022 (US$ Billion, AGR%)
  • Figure 168 F. Hoffmann-La Roche Ltd: R&D Expense, 2018-2022 (US$ Billion, AGR%)
  • Figure 169 Mayne Pharma Group Limited: Net Revenue, 2020-2023 (US$ Million, AGR%)
  • Figure 170 Mayne Pharma Group Limited: R&D Expense, 2020-2023 (US$ Million, AGR%)